Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ceapro Inc V.CZO

Chemicals Specialty Chemicals
Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

Recent & Breaking News (TSXV:CZO)

Canadian Investment Regulatory Organization Trading Halt - CZO

Canada NewsWire June 3, 2024

Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update

GlobeNewswire May 29, 2024

Ceapro Inc. Reports 2023 Financial Results and Operational Highlights

GlobeNewswire April 29, 2024

Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business

GlobeNewswire February 23, 2024

Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris

GlobeNewswire February 15, 2024

Canadian Investment Regulatory Organization Trade Resumption - CZO

Canada NewsWire December 14, 2023

Canadian Investment Regulatory Organization Trading Halt - CZO

Canada NewsWire December 14, 2023

Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases

GlobeNewswire December 13, 2023

Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights

GlobeNewswire November 29, 2023

Ceapro starts studies of flagship product for inflammation

Jocelyn Aspa November 27, 2023

Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases

GlobeNewswire November 27, 2023

Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology

GlobeNewswire November 7, 2023

Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update

GlobeNewswire August 29, 2023

Ceapro extends its agreement with Symrise

Jocelyn Aspa August 25, 2023

Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise

GlobeNewswire August 25, 2023

Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation

GlobeNewswire July 18, 2023

Ceapro to Participate in the Virtual Investor Summer Spotlight Series

GlobeNewswire July 5, 2023

Ceapro Announces Results of 2023 Shareholders' Meeting

GlobeNewswire June 7, 2023

Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update

GlobeNewswire May 25, 2023

Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases

GlobeNewswire May 23, 2023